Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis

Graft-versus-host disease (GVHD) is a significant obstacle to successful allogeneic hematopoietic stem cell transplantation (allo-HSCT), a curative treatment for many hematologic malignancies. Acute GVHD occurs when alloreactive donor T cells recognize recipient antigens as foreign and attack host tissues, especially in the liver, gut, and skin. Despite standard prophylaxis, acute GVHD incidence rates are approximately 30% to 50% in related donor HLA-matched transplants and as high as 50% to 70% in unrelated donor transplants [1].

Source: Biology of Blood and Marrow Transplantation - October 20, 2017 Category: Hematology Authors: Austin P. Huffman, Lee P. Richman, Lisa Crisalli, Alex Ganetsky, David L. Porter, Robert H. Vonderheide, Ran Reshef Source Type: research